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Abstract
Tumor-initiating cells (TICs) are a sub-population of cells that exhibit a robust ability to self-
renew and contribute to the formation of primary tumors, the relapse of previously treated tumors, 
and the development of metastases. TICs have been identified in various tumors, including those 
of the breast, and are particularly enriched in the basal-like and claudin-low subtypes of breast 
cancer. The signaling pathways that contribute to the function and maintenance of TICs are under 
intense study. We explored the potential involvement of the NF-κB family of transcription factors 
in TICs in cell lines that are representative of basal-like and claudin-low breast cancer. NF-κB was 
found to be activated in breast cancer cells that form tumorspheres efficiently. Moreover, both 
canonical and non-canonical NF-κB signaling is required for these cells to self-renew in vitro and 
to form xenograft tumors efficiently in vivo using limiting dilutions of cells. Consistent with this, 
canonical and non-canonical NF-κB signaling is activated in TICs isolated from breast cancer cell 
lines. Experimental results indicate that NF-κB promotes the function of TICs by stimulating 
epithelial-to-mesenchymal transition (EMT) and by upregulating the expression of the 
inflammatory cytokines IL-1β and IL-6. The results suggest the use of NF-κB inhibitors for 
clinical therapy of certain breast cancers.
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Tumors are comprised of a heterogeneous population of cells, including bulk epithelial 
tumor cells, inflammatory cells, and a sub-population of cells termed cancer stem cells or 
tumor-initiating cells (TICs) (1). The primary characteristic of TICs is their ability to self-
renew, which is measured in vitro by the formation of spheroid cellular structures termed 
tumorspheres (2, 3). Additionally, TICs exhibit elevated motility and invasiveness in vitro 
that correlates with high metastatic potential in vivo (4–6), and are frequently radio- (7, 8) 
and chemoresistant (9, 10). Importantly, TICs are thought to drive the progression of 
primary tumors, promote tumor recurrence, and stimulate the development of metastases at 
distance sites (4, 5). The importance of TICs in the clinical outcome of breast cancer is 
evidenced by the observation that an increase in their abundance following initial systemic 
treatment correlates with worse prognosis (11). TICs have been observed in multiple 
subtypes of human breast cancer (12) and are particularly enriched in the basal-like and 
claudin-low subtypes (12–14).
The NF-κB family of transcription factors contains five members, p65 (RelA), RelB, c-Rel, 
p105/p50, and p100/p52 (15, 16). In most cells, NF-κB proteins exist as hetero- and 
homodimers in the cytoplasm bound to a class of inhibitory proteins called IκBs. In response 
to a wide variety of cellular stimuli, NF-κB becomes active via one of two pathways. In the 
canonical pathway, NF-κB activation depends on the IκB kinase complex (IKK), which 
contains two catalytic subunits, IKKα and IKKβ, and a regulatory subunit, IKKγ or NEMO. 
Upon stimulation, IκBα is phosphorylated at Ser32/36 by IKK in a manner that requires 
IKKβ, which results in the degradation of IκBα and the release of the p65-p50 dimer to 
accumulate in the nucleus (15). Phosphorylation of p65 at Ser536 by IKK is also important 
for its activity (17). Separately, the non-canonical NF-κB pathway is regulated by an IKKα 
homodimer. In this cascade, RelB-p100 heterodimers are processed to RelB-p52 
heterodimers in a manner that depends on IKKα. In the nucleus, NF-κB dimers activate 
genes including those involved in cell cycle regulation (e.g. cyclin D1), suppression of 
apoptosis (e.g. Bcl-2 and Bcl-xL), and inflammation (e.g. cytokines such as IL-6 and IL-8) 
(15).
Activation of NF-κB is strongly associated with oncogenesis, as it is known to promote the 
oncogenic phenotype through processes including cell proliferation, inflammation, cell 
invasion and suppression of apoptosis (18, 19). Consistent with this, both canonical and non-
canonical NF-κB signaling is activated in human breast cancer cell lines and primary breast 
tumors (20–24). Recently, IKK/NF-κB was shown to be important in TICs isolated from 
HER2+ breast cancer (25, 26). Others have observed that NF-κB functions to promote 
proliferation in basal-like breast cancer cells (27). Here, we have explored a potential role 
for NF-κB in TIC function in cells derived from basal-like and claudin-low breast cancer 
cells. Specifically, we show that NF-κB signaling is more highly activated in breast cancer 
cell lines that undergo efficient self-renewal. Moreover, inhibition of either canonical or 
non-canonical NF-κB signaling blunts the self-renewal of human breast cancer cells in vitro. 
Inhibition of NF-κB also reduces the formation of xenograft tumors in the mammary fat 
pads of nude mice in vivo. Mechanistically, we provide evidence that NF-κB promotes the 
function of TICs through stimulation of epithelial-to-mesenchymal transition (EMT) and the 
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production of inflammatory cytokines that are encoded by NF-κB target genes. Collectively, 
these data demonstrate that canonical and non-canonical NF-κB signaling play critical roles 
in the function of TICs derived from basal-like and claudin-low subtypes of breast cancer 
cells.
Results
NF-κB signaling is preferentially activated in tumorsphere-forming breast cancer cells
Cell lines representing the basal-like subtype (SUM149) and the claudin-low subtype 
(MDA-MB231) of breast cancer were utilized to investigate the role of NF-κB in the 
function of TICs. A hallmark of breast cancer TICs is the ability to drive the formation of 
spheroid structures termed tumorspheres (or mammospheres) in serum-free culture, which 
reflects the ability of these cells to self-renew in vitro (reviewed in (2, 28)). It was observed 
that both SUM149 and MDA-MB231 cells efficiently form tumorspheres over at least three 
cycles of culture (Figure 1a). It was then determined whether the ability of basal-like and 
claudin-low cancer cells to form tumorspheres correlates with the level of basal NF-κB 
activation in the bulk population. Importantly, both p65 and IκBα are preferentially 
phosphorylated in SUM149 and MDA-MB231 cells that form tumorspheres efficiently, 
compared to MCF10A cells which form tumorspheres less efficiently (Figure 1b) (29).
Canonical NF-κB signaling is required for basal-like breast cancer cells to efficiently self-
renew in vitro
To inhibit NF-κB, SUM149 cells were stably infected with a retrovirus expressing either an 
empty vector or IκBα-SR (a modified form of IκBα that cannot be phosphorylated) and 
selected with puromycin (Figure 2a). To assay for self-renewal, 100 SUM149 cells 
expressing empty vector or IκBα-SR were plated in serum-free media on low-adhesion 
plates and the number of tumorspheres was determined five days later. Importantly, cells in 
which NF-κB was inhibited by expression of IκBα-SR formed three-fold fewer 
tumorspheres than control cells expressing an empty vector (Figure 2b). To confirm these 
results, an RNAi knockdown approach was utilized. SUM149 cells were stably infected with 
an empty lentiviral vector, a lentivirus encoding a scrambled shRNA, or a lentivirus 
encoding an shRNA construct targeting p65 or IKKβ (Figure 2c). Subsequently, self-
renewal of these cells was assayed through tumorsphere formation as described above. 
Importantly, knockdown of either p65 or IKKβ resulted in a statistically significant, 
approximately five-fold reduction in the ability of SUM149 cells to form tumorspheres 
(Figure 2d). Notably, expression of IκBα-SR or knockdown of IKKβ or p65 does not alter 
the growth of SUM149 cells, as assessed by MTT assay (Supplemental Figures 1a and 1b). 
Additionally, further analysis demonstrated that tumorspheres were arising from single cells 
(data not shown). This indicates that any variation in the formation of tumorspheres is due to 
reduced self-renewal, rather than an inhibition of cell growth or cytotoxicity. Interestingly, 
shRNA-based knockdown of IKKα (Figure 2c) induced a statistically significant, 
approximately five-fold reduction in the self-renewal of SUM149 cells (Figure 2d) without 
altering overall cell growth (Supplemental Figure 1b). Treatment with an IKKβ inhibitor 
(compound A, (30)) blocked both basal and TNFα-induced phosphorylation of p65 (Figure 
2e) and led to a reduction in tumorsphere formation that was very similar to the results 
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obtained with shRNA knockdown of different IKK and NF-κB subunits (Figure 2f). These 
data demonstrate that canonical NF-κB signaling, driven by IKK, promotes self-renewal in 
basal-like breast cancer cells (also see below).
In addition to the breast cancer cells analyzed above, we analyzed the role of NF-κB in the 
claudin-low representative cell line SUM159 (reviewed in (31, 32)). Notably, similar results 
were obtained in SUM159 cells compared to SUM149 cells. Specifically, inhibition of IKK 
with compound A blocked NF-κB activity as measured by inhibition of phosphorylation of 
p65 and IκBα (Supplemental Figure 2a). Additionally, and consistent with the findings 
using basal-like breast cancer cells, compound A blocked the formation of tumorspheres 
derived from SUM159 cells (Supplemental Figure 2b).
Non-canonical NF-κB activity is required for breast cancer cells to self-renew in vitro
As shown above, IKKα contributes to the self-renewal of basal-like breast cancer cells. 
IKKα typically acts in non-canonical NF-κB signaling (reviewed in (15, 16)), although it 
has recently been reported to promote canonical NF-κB signaling in breast cancer cells of 
the HER2+ subtype (33). Knockdown with p100/p52 siRNA efficiently reduced the 
precursor 100 kD component and almost completely eliminated the processed p52 subunit 
(Figure 3a). Consistent with the IKKα knockdown results (Figures 2c and 2d), a statistically 
significant reduction in tumorsphere formation was observed in cells in which p100/p52 was 
inhibited by siRNA (Figure 3b). To further address a role for non-canonical NF-κB in 
promoting breast cancer cell tumorsphere formation, RelB was knocked down with siRNA 
(Figure 3a). As shown in Figure 3b, knockdown of this component of the non-canonical NF-
κB pathway suppressed tumorsphere formation in both SUM149 and MDA-MB231 cells. 
These data, along with those shown in Figure 2, demonstrate that both canonical and non-
canonical NF-κB are two signaling pathways that promote the self-renewal of breast cancer 
cells.
NF-κB promotes the self-renewal of breast cancer cells in vivo
In vivo, self-renewal is assayed by measuring the ability of cells to establish primary tumors 
when injected at limiting dilutions, which is specifically associated with the function of 
TICs (2, 34, 35). To directly test the role of NF-κB in the self-renewal of basal-like breast 
cancer cells in vivo, SUM149 cells expressing empty vector or IκBα-SR at low (102 
cells/100 µL) or high (106 cells/100 µL) density were prepared. These cells were injected 
into the mammary fat pad of nude mice and monitored as described in the methods. In these 
experiments, cells in which NF-κB signaling was deficient exhibited both delayed tumor 
onset and reduced overall tumor size (Table 1). Specifically, while the high density of 
SUM149 cells expressing empty vector formed palpable tumors at six weeks and reached an 
average tumor volume of 138 mm3 by ten weeks, the high density of SUM149 cells 
expressing IκBα-SR did not form palpable tumors until week 8 and these tumors maintained 
a significantly smaller size (11 mm3) at week 10 (Table 1). Importantly, the low density of 
SUM149 cells expressing empty vector formed palpable tumors at week 9 and these tumors 
continued to increase in size at a significant rate (Table 1). Conversely, the low density of 
SUM149 cells expressing IκBα-SR did not form tumors (Table 1). These data demonstrate 
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that NF-κB is required for xenograft-generated tumorigenesis in a context (limiting dilutions 
of cells, reviewed in (2)) that depends significantly on self-renewal.
Canonical and non-canonical NF-κB are activated in breast cancer TICs and required for 
maintenance of TICs in the bulk population
The cell surface profile most commonly associated with breast cancer TICs is CD44+CD24- 
(7, 13, 34, 36–38), although CD44+, EpCAM+, or ALDEFLUOR-positivity (which depends 
on the activity of the enzyme ALDH1) are also indicative of this sub-population of cells (12, 
26, 34, (39–43). After examining the various cell surface profiles previously reported to 
enrich for TICs (data not shown), we chose to analyze CD44+ cells, which could be 
identified and isolated efficiently and, more importantly, efficiently self-renew (see below). 
By calculating the percentage yield from the isolation protocol, bulk populations of both the 
SUM149 (Figures 4g and 4h) and MDA-MB231 cell lines (data not shown) were found to 
contain approximately 10% CD44+ cells. This percentage is lower than earlier reports (2, 
12, 44), although different groups have reported a range of the proportion of TICs even 
within the same cell line, particularly when different cell surface markers are utilized (12, 
44).
While the bulk population and CD44− cells each contain only a small proportion of cells 
that are positive for CD44, nearly all the cells in the CD44-isolated population robustly 
express CD44 (Figure 4a). This confirms that the isolation protocol successfully enriches for 
CD44+ cells. Notably, CD44+ cells form tumorspheres significantly more efficiently than 
CD44− cells (Figure 4b), which demonstrates that the CD44+ isolation protocol enriches for 
TIC function. Given that NF-κB is required for the self-renewal of TICs (Figures 2 and 3), 
the activation of NF-κB was assessed in lysates from breast cancer TICs (CD44+ cells) 
compared to lysates isolated from the bulk population of cells and non-TICs (CD44− cells). 
Importantly, phosphorylation of p65 (Figure 4c) and levels of p52 (Figure 4d) are detected 
in CD44+ cells in both SUM149 and MDA-MB231 cells, indicating that both canonical and 
non-canonical NF-κB signaling is activated in breast cancer TICs. As before, the role of NF-
κB in TICs of the claudin-low SUM159 cells was also assessed. Specifically, CD44+ cells 
isolated from SUM159 cells also exhibit elevated NF-κB activity, as measured by 
phosphorylation of p65 (Supplemental Figure 2c).
To determine if pathways upstream of NF-κB are also activated in breast cancer TICs, 
phosphorylation of IKKα and IKKβ was assessed by immunoblot of cellular lysates 
prepared from the bulk population of SUM149 cells and its TIC and non-TIC counterparts. 
In support of the concept that NF-κB activation is IKK-dependent in these cells, an 
increased signal for phosphorylated IKKα/β was observed in TICs isolated from SUM149 
cells (Figure 4e). This is also consistent with evidence that canonical and non-canonical NF-
κB pathways are important in TICs (Figures 2, 3, 4c, and 4d). Finally, the activation of 
TAK1, a kinase that is an upstream activator of IKK (45), was examined. Similar to IKK, 
phosphorylation of TAK1, which is indicative of its activation (46), was enriched in CD44+ 
cells (Figure 4f).
Given that NF-κB is preferentially activated in breast cancer TICs (Figures 4a-4f) and 
required for their self-renewal in vitro and in vivo (Figures 2 and 3 and Table 1), it was 
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determined whether NF-κB is important in the maintenance of TICs in the bulk population 
of basal-like breast cancer cells. To this end, the percentage of TICs in the bulk population 
of SUM149 cells was determined in the presence or absence of overexpression of IκBα-SR. 
The resulting data showed that inhibition of NF-κB reduced the percentage of CD44+ cells 
by approximately 50% (Figure 4g). Similarly, stable knockdown of p65, IKKβ, or IKKα 
each reduced the percentage of CD44+ cells by approximately 50% (Figure 4h). Taken 
together, these data demonstrate that both canonical and non-canonical NF-κB signaling is 
preferentially activated in breast cancer TICs, consistent with observations from TICs in the 
bulk population of cells (Figures 2 and 3), and that NF-κB is important for the maintenance 
of the TIC population.
NF-κB promotes expression of markers of EMT in TICs and TGFβ-induced self-renewal
EMT is a process by which an epithelial cell releases from the basement membrane and 
transforms into a spindle-like, mesenchymal cell expressing vimentin and fibronectin 
(reviewed in (47)). EMT has been demonstrated to promote the self-renewal of immortalized 
breast cells (36, 37), but this has not been examined in specific subtypes of breast cancer 
cells. NF-κB is one of multiple signaling pathways implicated in the regulation of EMT, as 
activation of NF-κB is required for EMT that occurs during Ras-driven transformation (48). 
Thus, we hypothesized that NF-κB promotes the function of breast cancer TICs by 
stimulating EMT. Expression of mesenchymal markers was analyzed in the bulk population 
of SUM149 or MDA-MB231 cells, and in CD44+ and CD44− cells. Both vimentin and 
fibronectin were detected in the bulk population as well as CD44+ and CD44− cells (data 
not shown). Importantly, expression of mesenchymal markers depends on NF-κB, as 
vimentin expression is decreased in the bulk population of SUM149 and MDA-MB231 cells 
expressing IκBα-SR (Figure 5a). To extend these results, knockdown of the RelA/p65 NF-
κB subunit reduced vimentin and fibronectin expression in SUM149 cells (Supplementary 
Figure 3).
TGFβ is a well-characterized inducer of EMT and has been shown to promote the self-
renewal of at least immortalized breast cancer cells (36). To first confirm that TGFβ 
promotes self-renewal of basal-like breast cancer cells, 100 SUM149 cells expressing empty 
vector were plated on low-adhesion plates in serum-free media and treated every other day 
for seven days with 10 ng/mL TGFβ or vehicle control. Such treatment induced a 
statistically significant, three-fold increase in the number of tumorspheres formed by these 
cells (Figure 5b), suggesting that EMT is important for the function of TICs in basal-like 
breast cancer cells. Importantly, it was investigated whether the ability of TGFβ-induced 
EMT to stimulate self-renewal of basal-like breast cancer cells depends on NF-κB. 
Specifically, SUM149 cells expressing IκBα-SR to inhibit NF-κB were also included in the 
above TGFβ experiment. As previously observed (Figure 2b), expression of IκBα-SR 
reduced the self-renewal of SUM149 cells (Figure 5b). TGFβ treatment of SUM149 cells 
expressing IκBα-SR resulted in the formation of a significantly smaller number of 
tumorspheres than TGFβ treatment of cells with proficient NF-κB signaling (Figure 5b). 
These data suggest that NF-κB promotes the self-renewal of basal-like breast cancer cells at 
least in part by stimulating EMT.
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IL-1β and IL-6 stimulate the self-renewal of basal-like breast cancer cells downstream of 
NF-κB
Inflammatory cytokines that are NF-κB target genes have been demonstrated to be involved 
in self-renewal (29, 49, 50), but the role of NF-κB in this process has not been thoroughly 
examined. We hypothesized that a subset of cytokine NF-κB target genes may be important 
to promote breast cancer TICs. To test this hypothesis, SUM149 cells were examined for 
expression of three inflammatory cytokines (IL-1β, IL-6, and IL-8) and for whether NF-κB 
is involved in regulating their expression in these cells. Analysis of mRNA expression by 
real-time PCR demonstrated that the IκBα-SR-expressing cells exhibit reduced levels of 
IL-1β, IL-6, and IL-8 mRNAs compared to vector control cells (Figure 6a). Additionally, 
ELISA analysis revealed significantly decreased levels of secreted IL-1β, IL-6, and IL-8 in 
the media of SUM149 cells in which NF-κB is inhibited compared to the vector control cells 
(Figure 6b). These data confirm that NF-κB is critical for the expression and secretion of 
IL-1β, IL-6, and IL-8 in basal-like breast cancer cells.
To determine whether IL-1β, IL-6, or IL-8 promote the self-renewal of basal-like breast 
cancer cells, 100 SUM149 cells expressing an empty vector were plated on low-adhesion 
plates in serum-free media and treated every other day for seven days with either IL-1β, 
IL-6, IL-8 or vehicle control. Tumorspheres were enumerated following the completion of 
this treatment schedule. Importantly, treatment of SUM149 cells expressing empty vector 
with either IL-1β or IL-6 potently increased the number of tumorspheres by four-fold and 
two-fold, respectively (Figure 6c). These data suggest that IL-1β and IL-6 are important 
modulators of the ability of basal-like breast cancer cells to self-renew. Treatment of 
SUM149 cells with CXCL7, the product of an NF-κB target gene, produced small increases 
in the ability of these cells to form tumorspheres (data not shown). Conversely, treatment 
with exogenous IL-8 failed to promote the formation of tumorspheres in control SUM149 
cells (Figure 6c). Consistent with the results described above, addition of an IL-6 receptor 
antagonistic antibody suppressed tumorsphere formation approximately 25% and addition of 
recombinant IL-1β receptor antagonist suppressed tumorsphere formation approximately 
30% (Supplementary Figure 4).
Since IL-1β and IL-6 are known NF-κB target genes (51) and were upregulated by NF-κB in 
SUM149 cells (Figures 6a and 6b), we investigated whether NF-κB promotes self-renewal 
by inducing their expression and secretion. Specifically, we tested whether treatment with 
IL-1β or IL-6 can rescue the ability to self-renew in SUM149 cells in which NF-κB is 
inhibited. To do so, the above experiment was also performed using SUM149 cells 
expressing IκBα-SR. As before (Figure 2B), expression of IκBα-SR reduces the ability of 
untreated SUM149 to form tumorspheres (Figure 6C). Notably, treatment with either IL-1β 
or IL-6, but not IL-8, partially rescued the ability of IκBα-SR-expressing cells to form 
tumorspheres (Figure 6c). These data indicate that IL-1β and IL-6 promote self-renewal of 
basal-like breast cancer cells downstream of NF-κB.
Discussion
Most solid tumors, including those of the breast (52), are characterized by a hierarchy of 
cells including a sub-population of cells that can self-renew and give rise to the 
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differentiated cells that comprise the bulk of the tumor. These TICs promote tumor 
initiation, cellular motility and invasiveness, tumor recurrence, and are typically radio- and 
chemoresistant. As such, characterizing the functional and phenotypic differences between 
the bulk population of cancer cells and TICs is critical to understanding tumorigenesis and 
to gain insight into new approaches for cancer therapy. The transcription factor NF-κB is 
widely implicated in a variety of oncogenic mechanisms in both hematologic malignancies 
as well as solid tumors, including cancer cell proliferation, survival, and metastasis (18, 19). 
Here, we have shown the involvement of NF-κB in promoting TICs in a basal-like breast 
cancer cell line, SUM149, and two claudin-low lines, MDA-MB231 and SUM159. 
Interestingly, both canonical and non-canonical NF-κB appear to be important in promoting 
TICs in these cancer cell lines. It will be interesting to determine if distinct, or overlapping 
functions of these two pathways are operative in the maintenance of TICs. Work by others 
has indicated the association of NF-κB activity with other TICs. For example, prostate 
cancer TICs exhibit increased canonical NF-κB activity (53). Also, published work indicates 
that canonical NF-κB signaling is important in TICs in the HER2+ breast tumor subtype 
(25, 26, 54). One study utilized inhibitors which are not specific to NF-κB to suggest an 
involvement of NF-κB in promoting MCF7 breast cancer tumorspheres (55).
We propose that NF-κB promotes the function of TICs through several mechanisms. First, 
NF-κB may promote TIC self-renewal by stimulating EMT. Second, NF-κB promotes TICs 
by stimulating the expression of cytokines, such as IL-1β and IL-6. Notably, IL-6 has been 
implicated in the induction of EMT in breast cancer cells (56). Several reports support the 
finding that IL-6 promotes the function of TICs downstream of NF-κB. MCF10A cells 
transformed by Src gain the ability to form tumorspheres in a manner that depends on 
expression of IL-6 (29). Additionally, it was found that treatment of a claudin-low breast 
cancer cell line with IL-6 increased the proportion of TICs (50). That NF-κB upregulates the 
expression of many cytokines, and correspondingly can be activated downstream of these 
cytokines, indicates an important mechanism for sustaining NF-κB activation and promoting 
its TIC self-renewal properties in certain cancers. Additional roles for NF-κB in TICs likely 
include the upregulation of other key genes. Given the potential benefit of targeting TICs in 
breast cancer patients, the identification of NF-κB as a key regulator of TICs in basal-like 
and claudin-low breast cancer cells, along with previous work studying NF-κB in Her2+ 
TICs, represents a significant opportunity for the development of more effective 
chemotherapeutics for breast cancer.
Materials and Methods
Cell culture and reagents
SUM149, MDA-MB231, SUM159, and MCF10A cells were maintained as described 
(Supplementary Materials). Details regarding shRNA constructs and antibodies are also 
found in Supplementary Materials.
Tumorsphere formation assay
Cells growing adherently in serum-containing media were trypsinized with TrypLE Select 
(Invitrogen) to generate a single cell solution and then enumerated using a hemocytometer. 
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Subsequently, 100 cells per well were plated in 3 mL of Mammocult© media (Stem Cell 
Technologies) on 6-well low-adhesion plates (Corning). Cells were treated with compound 
A, TGFβ, cytokines, or vehicle controls as described in the text. The number of 
tumorspheres formed per well were counted visually. Cell density is a critical parameter in 
the tumorsphere formation assay and cells may aggregate if cell density is too high (28). As 
such, we ensured that a disperse, low density (100 cells in 3 mL of media) solution of cells 
was prepared for each tumorsphere formation assay to avoid cell aggregation. Furthermore, 
plates were not moved during the growth period, to avoid cell aggregation. These 





Cell sorting was performed using a Beckman-Coulter (Dako) CyAn and FlowJo software. 
See Supplementary Materials.
Isolation of TICs
Cells were trypsinized using TrypLE Select (Invitrogen) and dissociated by incubation in 
Accutase (Invitrogen) for 15 minutes at 37°C. The resulting cell solution was passed through 
a pre-separation filter (Miltenyi Biotec) to generate a single cell suspension. Cells were then 
incubated with 100 µL of Dead Cell Removal microbeads (Miltenyi Biotec) per 107 cells for 
15 minutes at room temperature. Subsequently, the cell and microbead solution was 
resuspended in 20 mL MACS buffer (Miltenyi Biotec) passed through an LS column 
(Miltenyi Biotec) that was pre-moistened with MACS buffer and placed in a magnetized 
field. Live cells from the eluate were collected. Next, the resulting live cells were 
resuspended in 100 µL of MACS buffer per 107 cells and incubated with 75 µL CD44 
microbeads (Miltenyi Biotec) and 75 µL FcR blocking reagent (Miltenyi Biotec) per 107 
cells for 30 minutes at 4°C. Subsequently, the cell and microbead solution was resuspended 
in 20 mL MACS buffer (Miltenyi Biotec) passed through a LS column (Miltenyi Biotec) 
that was pre-moistened with MACS buffer and placed in a magnetic field. The CD44− cells 
in the eluate were collected, then the LS column was removed from the magnetized field, 
and the CD44+ cells were collected from the column in 5 mL MACS buffer.
MTT
The MTT assays were performed as previously described (57) using CellTiter cell viability 
reagent (Promega). See Supplementary Materials.
Enzyme-linked immunosorbent assay (ELISA)
ELISA kits (BD Biosciences) were utilized according to the manufacturer’s instructions.
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Real-time PCR was performed and analyzed as previously described (58) using Taqman 
Gene Expression Assay primer-probe sets from Applied Biosystems.
Xenograft tumor formation
Cells were trypsinized with TrypLE Select (Invitrogen), a single cell solution generated, and 
the cells were enumerated using a hemocytometer. Cell solutions were generated in 50:50 
media:Matrigel (BD Biosciences) at concentrations of 106 or 102 cells/100 µL. 100 µL of the 
resulting solutions were orthotopically injected into the mammary fat pad of athymic nude-
Foxn1nu mice (Harlan Laboratories). Injection of each cell solution was repeated in 
triplicate. All murine studies were conducted in accordance with guidelines from the UNC 
Institutional Animal Care and Use Committee on approved protocol 08-266.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. NF-κB signaling is preferentially activated in tumorsphere-forming breast cancer cells
(A) Primary and tertiary tumorspheres formed by the indicated bulk populations of basal-
like and claudin-low breast cancer cells in serum-free culture on low-adhesion plates. (B) 
Phosphorylation of p65 and IκBα as markers of NF-κB activation in the indicated bulk 
populations of breast cancer cells (SUM149 and MDA-MB231) or immortalized breast 
(MCF10A) cells.
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Figure 2. Canonical NF-κB signaling is required for basal-like breast cancer cells to efficiently 
self-renew
(A) Immunoblot of the indicated proteins in SUM149 cells stably expressing an empty 
vector or IκBα-SR. (B) Quantification of tumorspheres formed by 100 SUM149 cells 
expressing empty vector or IκBα-SR. (C) Immunoblot of the indicated proteins by 100 
SUM149 cells stably infected with the indicated shRNA constructs. (D) Quantification of 
tumorspheres formed by 100 SUM149 cells stably expressing the indicated shRNA 
constructs. (E) Phosphorylation of p65 and IκBα as markers of activation of canonical NF-
κB signaling in SUM149 cells pre-treated with increasing doses of compound A and then 
treated with TNFα. (F) Quantification of tumorspheres formed by 100 SUM149 cells treated 
daily with 5 µM compound A.
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Figure 3. Non-canonical NF-κB signaling is required for basal-like breast cancer cells to self-
renew
(A) Immunoblot of the indicated proteins in SUM149 and MDA-MB231 cells expressing 
scrambled siRNA or siRNA targeting p100/p52 or RelB using the indicated antibodies. (B) 
Quantification of tumorspheres formed by 100 SUM149 or MDA-MB231 cells expressing 
the indicated siRNA constructs. p values for the right panel of (B) are: p = 0.0413 for 
scramble siRNA compared to p100/p52 siRNA and p = 0.0011 for scramble siRNA 
compared to RelB siRNA.
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Figure 4. Canonical and non-canonical NF-κB signaling is preferentially activated in TICs and 
required for the maintenance of TICs in breast cancer cells
(A) FACS analysis of the indicated populations of SUM149 cells stained with CD44-APC. 
(B) Quantification of tumorspheres formed by 100 cells from the indicated cell populations 
of SUM149 or MDA-MB231 cells. (C) Phosphorylation of p65 as a marker of activation of 
canonical NF-κB signaling in the indicated populations of SUM149 and MDA-MB231 cells. 
(D) Cleavage of p100 to p52 as a marker of activation of non-canonical NF-κB signaling in 
the indicated populations of SUM149 and MDA-MB231 cells. (E) Phosphorylation of IKKα 
and IKKβ in the indicated populations of SUM149 cells. (F) Phosphorylation of TAK1 in 
the indicated populations of SUM149 cells. (G, H) Percentage of TICs isolated from 
SUM149 cells stably expressing IκBα-SR (G) or the indicated shRNA constructs (H).
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Figure 5. NF-κB activation promotes expression of markers of EMT in TICs and TGFβ-induced 
self-renewal of basal-like breast cancer cells
(A) Immunoblot of vimentin in SUM149 or MDA-MB231 cells stably expressing an empty 
vector or IκBα-SR. (B) Quantification of tumorspheres formed by 100 SUM149 cells stably 
expressing empty vector or IκBα-SR, followed by treatment with vehicle control or TGFβ.
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Figure 6. IL-1β and IL-6 stimulate the self-renewal of basal-like breast cancer cells downstream 
of NF-κB
(A) Real-time PCR showing expression of IL-1β, IL-6, or IL-8 in the bulk population of 
SUM149 cells stably expressing an empty vector or IκBα-SR. (B) ELISA analysis showing 
the abundance of IL-1β, IL-6, or IL-8 in the media of SUM149 cells stably expressing empty 
vector or IκBα-SR. (C) Quantification of tumorspheres formed by 100 SUM149 cells 
expressing empty vector or IκBα-SR, followed by treatment with IL-1β, IL-6, IL-8 or 
vehicle control.
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Table 1
Inhibition of NF-κB signaling blunts tumorigenesis of limiting dilutions of basal-like 
breast cancer cells
Quantification of the average tumor volume of xenograft tumors formed in the mammary fat pad of nude mice 
following injection of limiting dilutions of SUM149 cells expressing an empty vector or IκBα-SR.
average tumor volume (mm3)
week 6 week 7 week 8 week 9 week 10
SUM149 vector
  102 cells — — — 1.33 8.25
  106 cells 8.33 4.67 24.67 83.25 137.58
SUM149 IκBα-SR
  102 cells — — — — —
  106 cells — — 10.67 10.67 10.67
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